Domain registration record

https://rdap.nic.gov/rdap/domain/fda.gov

Last checked: 10/23/2026, 12:52:18 AM UTC

The domain was registered on July 26, 2000. Its registration company is get.gov. Registration does not confirm that a business is trustworthy.

Website information

https://www.fda.gov/about-fda

Last checked: 10/23/2026, 12:52:31 AM UTC

About FDA | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home In this section Topic Paragraphs Call-To-Action Video Call-To-Action Title What Does FDA Do? Each day in America, you can trust the foods you eat and the medicines you take, thanks to the U.S. Food and Drug Administration. More than 18,000 FDA employees work in all 50 states and internationally to ensure the safety and effectiveness of human and veterinary medicines, biologics, and medical devices. We also regulate the safety of food, cosmetics, devices that emit radiation, and tobacco products. Learn More Call-To-Action Video Call-To-Action Title FDA at a Glance The FDA is a part of the Department of Health and Human Services. FDA-regulated products account for 20 cents of every dollar spent by U.S. consumers. Food and Drug Administration 10903 New Hampshire Ave Silver Spring, MD 20993 1-888-INFO-FDA (1-888-463-6332) Learn More Mission Organization Budget Contact What We Regulate What We Inspect Program Performance En español Jobs and Training Partnerships Doing Business with FDA Who We Are FDA employees work in all 50 states and internationally to protect public health. The FDA employs project managers, scientists, statisticians, administrators, communicators, analysts, lawyers, doctors, inspectors, consumer safety officers, and many others. FDA staff are like your family – mothers and fathers, neighbors, community members, caregivers, friends, and more. And just like your family, FDA staff and their families are directly impacted by the work they do every day. Learn More Leadership FDA Commissioner History Budgets Budget documentation for Fiscal Year 2025 and previous years. Reports and Forms Staff manual guides, user fee reports, budgets, strategic plans, economic analyses, and application forms, certification forms, and more. Performance Data FDA Data Dashboard, FDA-TRACK, openFDA, Recall Datasets, and more. FDA Acronyms and Abbreviations Search the FDA Acronyms and Abbreviations database. Plain Language How the FDA is implementing the Plain Writing Act and Plain Language Principles in our communications with you. About This Website Accessibility, privacy, and web policies. Contact FDA Follow FDA on Facebook Follow FDA on X Follow FDA on Instagram Follow FDA on LinkedIn View FDA videos on YouTube Subscribe to FDA RSS feeds Contact Number 1-888-INFO-FDA (1-888-463-6332) Back to Top Feedback

Website information

https://www.fda.gov/

Last checked: 10/23/2026, 12:52:31 AM UTC

- Skip to main content - Skip to FDA Search - Skip to footer links An official website of the United States government Here’s how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. - Search - Menu Search FDASubmit search Featured - Report a Product Problem - Contact FDA - FDA Guidance Documents - Recalls, Market Withdrawals and Safety Alerts - Press Announcements - Warning Letters - Advisory Committees - En Español Products - Food - Drugs - Medical Devices - Radiation-Emitting Products - Vaccines, Blood, and Biologics - Animal and Veterinary - Cosmetics - Tobacco Products Topics - About FDA - Combination Products - Regulatory Information - Safety - Emergency Preparedness - International Programs - News and Events - Training and Continuing Education - Inspections and Compliance - Science and Research Information For - Consumers - Patients - Industry - Health Professionals - Federal, State and Local Officials Topic Paragraphs FDA Launches New Program to Advance Neuroscience Medical Product Development The Neuroscience Advancement and Innovation Nexus is a new cross-center FDA program to advance the science, tools, and regulatory approaches needed to support the development of medical products for conditions affecting the brain and nervous system. Featured Topics Recalls Report a Problem Warning Letters Consumer Updates 483s EUAs 510Ks Guidance Documents Drug Databases Import Program FDA in Action \\ \\ Transparency Makes Modern Regulatory Science Stronger — FDA’s Transparency Roadmap \\ \\ FDA Approves First Heart Valve Designed to Grow with Children \\ \\ FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma \\ \\ Supporting and S Products We Regulate Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood, and Biologics Animal and Veterinary Cosmetics Tobacco Products Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players. Language Assistance Available: Español \| 繁體中文 \| Tiếng Việt \| 한국어 \| Tagalog \| Русский \| العربية \| Kreyòl Ayisyen \| Français \| Polski \| Português \| Italiano \| Deutsch \| 日本語 \| فارسی \| English - FDA Archive - About FDA - Accessibility - Visitor Information - Website Policies / Privacy - No FEAR Act - Vulnerability Disclosure Policy - FOIA - HHS.gov - USA.gov Contact FDA Follow FDA on Facebook Follow FDA on X Follow FDA on Instagram Follow FDA on LinkedIn View FDA videos on YouTube Subscribe to FDA RSS feeds Contact Number 1-888-INFO-FDA (1-888-463-6332) Back to Top Feedback .png) FDA.gov Site Customer Feedback Help us improve FDA.gov! We will use your responses to improve the experience for millions of people who visit FDA.gov. A red asterisk (\) indicates a required field. Success Thank you. Your feedback has been received. Error alert message 1\. Which of the following best categorizes the information you were looking for on FDA.gov today? \ Select oneFoodDrugsMedical DevicesRadiation-Emitting ProductsVaccines, Blood & BiologicsAnimal & VeterinaryCosmeticsTobacco ProductsOther 2\. Which of the following best describes the information you were looking for on FDA.gov today? \ Select oneRecall or foodborne illness outbreak informationWarning letters or enforcement actionsReport a problem (adverse event) with a productDispose of drugs or sharpsProduct approvalsDrug labelsSide effects of a productContact an FDA office or staff memberComplete or check registration for a product or facilityGet FDA organizational informationImport or export a product (including Prior Notice)Get a job with FDAGet trainingGet a formComment on a proposed guidance or ruleCheck a regulation, rule, or guidance (for regulated industry)COVID-19 informationAdvice/information about a medical device, drug, food, or other FDA-regulated productOther 3\. Did you find the information you were looking for on FDA.gov today? \ Yes Partially. I found some of the information I was looking for. No I'm still looking 4\. For this visit to the FDA site, which of the following roles best describes you? If you are a consultant or an attorney, please select the role of the individual or organization that you represent. \ Select oneConsumer, patient, or patient’s caregiverRegulated industry or businessHealthcare professional (includes physician, nurse, physician’s assistant, nurse practitioner, or pharmacist)Public health/Policy professionalScientist, researcherEducator, professor, teacher, or studentMedia/JournalistFDA Employee/ContractorsOther 5\. How frequently do you visit FDA.gov? \ This is my first time About once a year A couple of times a year Monthly Weekly Daily 6\. On a scale from 0-10, based on your experience today, how likely are you to recommend this website to a friend or colleague? \ 0 1 2 3 4 5 6 7 8 9 10 7) Overall, how satisfied or dissatisfied were you with your experience on the FDA website today? Navigation \ Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Look & Feel \ Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Using FDA’s search feature \ Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Understandability of the content \ Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Overall Experience \ Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Submit An official form of the United States government. Provided by Touchpoints OMB Approval 0910-0360 · Expiration Date 07/08/2026

Website information

https://www.fda.gov/about-fda/contact-fda

Last checked: 10/23/2026, 12:52:31 AM UTC

Contact FDA | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home About FDA Contact FDA About FDA In this section Resources for Former FDA Employees Report a product problem Tell us about a problem with an FDA-regulated product. We review every submission to monitor product safety. You can also check whether a product has a recall. Report a product problem Check product recalls Call us Speak to a product office or report a product problem over the phone. Healthcare providers can request the use of an investigational product. 1-888-INFO-FDA (1-888-463-6332) Contact an office Reach out to an office for any product-specific questions or concerns. Animal & Veterinary Cosmetics Drugs Foods Medical Devices Tobacco Vaccines, Biologics, Blood, Cell or Gene Therapy Inspections and Investigations National Center for Toxicological Research Office of the Chief Counsel Office of Media Affairs Reporters writing for a credentialed media outlet may contact FDA by using the request for comment form . Comment on open dockets For information on commenting on FDA’s proposed regulations and submitting citizen petitions, see Comment on Proposed Regulations and Submit Petitions . Request information under the Freedom of Information Act For information on submitting a request for information under the Freedom of Information Act (FOIA) on FDA and other components of the U.S. Department of Health and Human Services, see Freedom of Information . Request an FDA speaker FDA receives thousands of requests each year from trade associations and industry-based groups for speakers to participate in external meetings, conferences, and workshops that involve staff from the Office of the Commissioner as well as FDA Centers and Offices. Request an FDA Speaker Stay informed Our free e-mail alert service allows you to receive important FDA news and information as they become available. Subscribe to FDA Email Notifications Content current as of: 08/27/2026 Feedback Contact FDA Follow FDA on Facebook Follow FDA on X Follow FDA on Instagram Follow FDA on LinkedIn View FDA videos on YouTube Subscribe to FDA RSS feeds Contact Number 1-888-INFO-FDA (1-888-463-6332) Back to Top

Website information

https://www.fda.gov/about-fda/office-inspections-and-investigations/oii-foia-electronic-reading-room

Last checked: 10/23/2026, 12:52:31 AM UTC

OII FOIA Electronic Reading Room | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home About FDA FDA Organization Office of Inspections and Investigations OII FOIA Electronic Reading Room Office of Inspections and Investigations In this section About the OII Electronic Reading Room The Office of Inspections and Investigations (OII) Electronic Reading Room gives the public access to selected FDA inspection and related records from both U.S. and foreign facilities. Records are posted here either because FDA has chosen to share them proactively or because enough members of the public have requested them under the Freedom of Information Act (FOIA). See the Proactive Disclosure and Three or More Rule sections below for more details. Important Caveat: This database does not necessarily reflect all inspections or oversight activities that may satisfy the statutory inspectional requirements. For that reason, the absence of a particular facility from this public database should not be interpreted to mean that the facility has not been subject to appropriate regulatory oversight or that the inspection requirements have not been met. The frequency and timing of inspections are determined based on a variety of factors, including risk, compliance history, and available information. How Records Are Made Available How Records Are Made Available FDA posts records in this Reading Room through two distinct pathways: Proactive Disclosure and Three or More Rule under FOIA. Both are explained in the sections below. Records that do not qualify under either pathway will not appear here, even if an inspection took place. It is also important to know that some records posted here may have portions redaction. This is done to protect information that is not appropriate for public release, such as trade secrets, confidential commercial information, personal information, or details that could compromise ongoing regulatory or law enforcement actions. This is governed by 21 CFR Part 20, FDA's public information regulations. If you are looking for OII data sets, such as lists of inspection classifications or 483 observations, please visit the data sets page. For other OII documents, visit the OII home page or the FDA Warning Letter page . For inspection and related records maintained by other FDA programs or centers, visit the relevant center Reading Room on the main FDA Electronic Reading Room . Proactive Disclosure Under federal law (specifically 5 U.S.C. § 552(a)(2)), FDA is authorized and encouraged to post certain records online without waiting for someone to ask for them. This is called proactive disclosure. FDA does this when it determines that the public has a meaningful interest in the information and that sharing it serves the goals of transparency and accountability. You do not need to file a FOIA request to access proactively posted records; they are available to anyone who visits this page. However, proactive disclosure is selective. FDA reviews records and makes case-by-case decisions about what to post. Not every inspection record will be posted proactively, and the absence of a record does not mean it does not exist or that it cannot be requested through FOIA. Three or More Rule Federal law also requires FDA to post records online when three or more people or organizations have separately requested the same record through FOIA. See 5 U.S.C. § 552(a)(2)(D). This is known as the "three or more rule," and it is one of the key transparency requirements of the Electronic Freedom of Information Act Amendments of 1996. The idea behind this rule is straightforward: If enough members of the public are asking for the same record, it should be made available to everyone rather than processed one request at a time. This saves time for both the public and the agency. Many of the records you will find in this Reading Room are here because they met this threshold. If a record has not yet been requested three or more times and was not selected for proactive posting, it will not appear here, but it may still be available through a FOIA request . What This Reading Room Does Not Include What This Reading Room Does Not Include This Reading Room is not a comprehensive repository of all FDA inspection activity. There are several important reasons that certain records may not be available here, and we want to be transparent about all of them. When Records Are Temporarily Withheld One of the most important limitations involves inspections that are still open or where FDA is actively pursuing a compliance action. When FDA is in the middle of a regulatory response, posting the related inspection records could interfere with that process. Federal regulations (21 CFR 20.64(d)) allow FDA to temporarily withhold these records until the compliance action is completed or the matter is otherwise resolved. This means a facility may have been inspected, with records on file, that do not yet appear in this Reading Room simply because the regulatory process is still underway. Once the matter is closed, records may become available through proactive posting or a FOIA request. A record not found is not the same as a missing inspection. Records may not appear in this Reading Room because a compliance action is still underway, because the record has not been frequently requested, or because FDA has not determined that proactive release is appropriate. Other Categories of Records Not Included Here Records from other FDA centers and offices: Each center maintains its own FOIA Reading Room, which can be accessed through the main FDA Electronic Reading Room. Records withheld under FOIA exemptions: Even when a record exists, portions or all of it may be withheld if it falls under one of the nine FOIA exemptions. Form FDA 483s and EIRs: Not all inspectional observations (Form FDA 483s) or Establishment Inspection Reports (EIRs) are publicly posted. Whether a 483 or EIR appears in this Reading Room depen

Website information

https://www.fda.gov/about-fda/about-website/fdagov-archive

Last checked: 10/23/2026, 12:52:31 AM UTC

FDA.gov Archive | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home About FDA About This Website FDA.gov Archive About This Website In this section Archived content from fda.gov can be accessed through archive.org and Pagefreezer , which maintain historical snapshots of the FDA website. The archive allows you to view previous versions of FDA web pages and documents that may no longer be available on the current site. The content in the archive is for historical purposes only and is no longer being updated. The information may be outdated, links may no longer function, and the content may not be compliant with Section 508 of the Rehabilitation Act. We have kept our captures on the Archive-it platform for historical references. Our last capture on the Archive-It platform was in December of 2020. Go to the FDA.gov Web Archive page in Archive-It. Click the date for the snapshot you want to view. The FDA.gov home page appears. Browse through the site. Note that the search function on each page in the FDA.gov Web Archive is disabled. Use the search function above instead. Content current as of: 08/19/2026 Feedback Contact FDA Follow FDA on Facebook Follow FDA on X Follow FDA on Instagram Follow FDA on LinkedIn View FDA videos on YouTube Subscribe to FDA RSS feeds Contact Number 1-888-INFO-FDA (1-888-463-6332) Back to Top

Website information

https://www.fda.gov/about-fda/about-website/language-assistance-services

Last checked: 10/23/2026, 12:52:31 AM UTC

Language Assistance Services | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home About FDA About This Website Language Assistance Services About This Website In this section Español (Spanish) ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-877-696-6775. U.S. Food and Drug Administration (FDA) cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad o sexo. FDA no excluye a las personas ni las trata de forma diferente debido a su origen étnico, color, nacionalidad, edad, discapacidad o sexo. La FDA: Proporciona asistencia y servicios gratuitos a las personas con discapacidades para que se comuniquen de manera eficaz con nosotros, como los siguientes: Intérpretes de lenguaje de señas capacitados. Información escrita en otros formatos (letra grande, audio, formatos electrónicos accesibles, otros formatos). Proporciona servicios lingüísticos gratuitos a personas cuya lengua materna no es el inglés, como los siguientes: Intérpretes capacitados. Información escrita en otros idiomas. Si necesita recibir estos servicios, comuníquese con FDA al 1-877-696-6775. Si considera que la FDA no le proporcionó estos servicios o lo discriminó de otra manera por motivos de origen étnico, color, nacionalidad, edad, discapacidad o sexo, puede presentar un reclamo a la Office for Civil Rights (Oficina de Derechos Civiles) del Department of Health and Human Services de EE. UU. de manera electrónica a través del portal Office for Civil Rights Complaint Portal, disponible en , o bien, por correo postal a la siguiente dirección o por teléfono a los números que figuran a continuación: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) 繁體中文 (Chinese) 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1-877-696-6775。 U.S. Food and Drug Administration (FDA) 遵守適用的聯邦民權法律規定、不因種族、膚色、民族血統、年齡、殘障或性別而歧視任何人。FDA 不因種族、膚色、民族血統、年齡、殘障或性別而排斥任何人或以不同的方式對待他們。 FDA 向殘障人士免費提供各種援助和服務、以幫助他們與我們進行有效溝通、如： 合格的手語翻譯員 以其他格式提供的書面資訊（大號字體、音訊、無障礙電子格式、其他格式） 向母語非英語的人員免費提供各種語言服務，如： 合格的翻譯員 以其他語言書寫的資訊 如果您需要此類服務、請聯絡 FDA 撥打 1-877-696-6775 如果您認為 FDA 未能提供此類服務或者因種族、膚色、民族血統、年齡、殘障或性別而透過其他方式歧視您、您可以向U.S. Department of Health and Human Services的 Office for Civil Rights（民權辦公室）提交民權投訴、透過 Office for Civil Rights Complaint Portal 以電子方式投訴： ，或者透過郵寄或電話的方式投訴： U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C.20201 1-800-368-1019、800-537-7697 (TDD)（聾人用電信設備） Tiếng Việt (Vietnamese) CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-877-696-6775. U.S. Food and Drug Administration (FDA) tuân thủ luật dân quyền hiện hành của Liên bang và không phân biệt đối xử dựa trên chủng tộc, màu da, nguồn gốc quốc gia, độ tuổi, khuyết tật, hoặc giới tính. FDA không loại trừ mọi người hoặc đối xử với họ khác biệt vì chủng tộc, màu da, nguồn gốc quốc gia, độ tuổi, khuyết tật, hoặc giới tính. FDA: Cung cấp dịch vụ hỗ trợ miễn phí cho những người khuyết tật để giao tiếp với chúng tôi có hiệu quả, như: Thông dịch viên ngôn ngữ ký hiệu đủ năng lực Thông tin bằng văn bản ở các định dạng khác (chữ in lớn, âm thanh, định dạng điện tử có thể tiếp cận, các định dạng khác) Cung cấp miễn phí các dịch vụ ngôn ngữ cho những người có ngôn ngữ chính không phải là tiếng Anh, như: Thông dịch viên đủ năng lực Thông tin được trình bày bằng ngôn ngữ khác Nếu bạn cần những dịch vụ này, hãy liên hệ FDA theo số 1-877-696-6775. Nếu bạn tin rằng HHS không cung cấp những dịch vụ này hoặc phân biệt đối xử theo cách khác dựa trên chủng tộc, màu da, nguồn gốc quốc gia, độ tuổi, khuyết tật, hoặc giới tính, bạn có thể nộp đơn khiếu nại với U.S. Department of Health and Human Services, Office for Civil Rights (Văn Phòng Dân Quyền) bằng hình thức điện tử qua Office for Civil Rights Complaint Portal, có trên trang , hoặc qua đường bưu điện hoặc bằng điện thoại tại: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) 한국어 (Korean) 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-877-696-6775 번으로 전화해 주십시오. U.S Food and Drug Administration (FDA) 은(는) 관련 연방 공민권법을 준수하며 인종, 피부색, 출신 국가, 연령, 장애 또는 성별을 이유로 차별하지 않습니다. FDA은(는) 인종, 피부색, 출신 국가, 연령, 장애 또는 성별을 이유로 누군가를 배제하거나 다른 방식으로 대우하지 않습니다. FDA: 장애인들이 저희와 효과적으로 의사소통할 수 있도록 다음과 같은 무료 지원과 서비스를 제공합니다. 자격있는 수화 통역자 다른 형식의 서면 정보(큰 활자, 음성, 사용 가능한 전자 형식, 기타 형식) 주로 사용하는 언어가 영어가 아닌 이들에게는 다음과 같은 무료 언어 서비스를 제공합니다. 자격있는 통역자 다른 언어로 작성된 서면 정보 이러한 서비스가 필요하시면 FDA에 1-877-696-6775번으로 연락하십시오. FDA 이(가) 인종, 피부색, 출신 국가, 연령, 장애 또는 성별을 이유로 이러한 서비스를 제공하지 않거나 다른 방식으로 차별했다고 생각하시는 경우, 를 통한 전자 방식 또는 우편이나 전화로 Department of Health and Human Services, Office for Civil Rights(시민권 사무국)에 민원을 제출할 수 있습니다. 주소 및 연락처는 다음과 같습니다. U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Tagalog PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-877-696-6775. Sumusunod ang U.S. Food and Drug Administration (FDA) sa mga naaangkop na Pampederal na batas sa karapatang sibil at hindi nandidiskrimina batay sa lahi, kulay, bansang pinagmulan, edad, kapansanan o kasarian. Ang FDA ay hindi nagtatangi ng mga tao o hindi nagpapakita ng ibang pakikitungo dahil sa lahi, kulay, bansang pinagmulan, edad, kapansanan o kasarian. Ang FDA ay: Nagbibigay ng mga libreng tulong at serbisyo sa mga taong may kapansanan upang mahusay silang makipag-ugnayan sa amin, gaya ng: Mga kwalipikadong interpreter ng sign language Nakasu

Website policies

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Last checked: 10/23/2026, 12:52:31 AM UTC

Emergency Use Authorization | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home Emergency Preparedness and Response Public Health Preparedness and Response Medical Countermeasures (MCMs) MCM Legal, Regulatory and Policy Framework Emergency Use Authorization MCM Legal, Regulatory and Policy Framework In this section Image On June 29, 2026, the HHS Secretary determined that circumstances no longer exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic. On the basis of this determination, the HHS declaration authorizing emergency use of drug and biological products for COVID-19 will be terminated, effective June 29, 2027. On the effective date of this termination, the COVID-19 emergency use authorizations (EUA) for drug and biological products currently listed on this webpage will no longer be in effect. Drug/Biologics: On June 29, 2026, the HHS Secretary determined that circumstances no longer exist justifying the authorization of emergency use of (1) in vitro diagnostics for detection and/or diagnosis of the SARS-CoV-2 virus; (2) personal respiratory protective devices; and (3) medical devices, including alternative products used as medical devices. On the basis of this determination, the HHS declarations authorizing emergency use of these medical devices for COVID-19 will be terminated, effective December 26, 2026. On the effective date of this termination, the COVID-19 emergency use authorizations (EUA) for devices currently listed on this website will no longer be in effect. Devices: On this page: About Emergency Use Authorizations (EUAs) PREP Act EUA Guidance New World Screwworm (NWS) COVID-19 EUAs mpox EUAs Vaccines Diagnostic tests (monkeypox virus) Other Current EUAs Pandemic Influenza A Viruses and Influenza A Viruses with Pandemic Potential: EUA Information Related Links Español About Emergency Use Authorizations (EUAs) The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against chemical, biological, radiological, and nuclear (CBRN) threats including infectious diseases, by facilitating the availability and use of medical countermeasures (MCMs) needed during public health emergencies. Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act ), when the Secretary of HHS declares that an emergency use authorization is appropriate, FDA may authorize unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when certain criteria are met, including there are no adequate, approved, and available alternatives. The HHS EUA Declaration to support such use must be based on one of four types of determinations of threats or potential threats by the Secretary of HHS, Homeland Security, or Defense. HHS EUA Declarations, and associated determinations, supporting use of EUAs are described below. Please note that an HHS EUA Declaration is distinct from, and not dependent on, a Public Health Emergency (PHE) Declaration under section 319 of the PHS Act. Information on terminated and revoked EUAs can be found in archived information . Public Readiness and Emergency Preparedness Act (PREP Act) Information on the PREP Act can be found here . The PREP Act amended the Public Health Service Act (PHS Act) to add section 319F-3 (42 U.S.C. 247d-6d) to allow HHS to issue a declaration to provide immunity (except for willful misconduct) for activities related to administration or use of ‘covered countermeasures,’ defined to include medical products authorized for emergency use. This PREP Act Declaration is distinct from, and not dependent on, HHS EUA Declarations or section 319 PHE Declarations. Guidance In January 2017, FDA finalized the guidance: Emergency Use Authorization of Medical Products and Related Authorities . For more information, please see the January 13, 2017 Federal Register notice . Printable PDF (288 KB) In addition, in January 2014, FDA issued a question and answer document (PDF, 762K) to respond to questions raised by public health stakeholders about PAHPRA’s amendments to the EUA authority and establishment of new authorities related to the emergency use of MCMs during CBRN emergencies. New World Screwworm (NWS) Effective August 18, 2025 , pursuant to section 564 of the FD&C Act, the HHS Secretary: Determined that there is a significant potential for a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad and that involves New World Screwworm ( Cochliomyia hominivorax ); and declared that circumstances exist justifying the authorization of emergency use of animal drugs to treat or prevent New World Screwworm myiasis in animals subject to the terms of any authorization issued under that section. These actions permit FDA to issue EUAs for animal drugs for the treatment or prevention of NWS myiasis in animals. Upon issuance, information for each EUA will be added to the website here: New World Screwworm: Information for Veterinarians | FDA Additional information: Animal Drugs for New World Screwworm | FDA Determination of a Significant Potential for a Public Health Emergency and Declaration that Circumstances Exist Justifying an Authorization Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b) Coronavirus Disease 2019 (COVID-19) EUA Information Coronavirus Disease (COVID-19) updates from FDA The HHS Secretary

Website information

https://www.fda.gov/about-fda/visitor-information

Last checked: 10/23/2026, 12:52:31 AM UTC

Visitor Information | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home About FDA Visitor Information About FDA In this section Welcome to the FDA! The FDA headquarters is on the White Oak campus in Silver Spring, Maryland, in Montgomery County. The FDA has additional offices across the U.S. Visitors to White Oak can use public transportation (Metro train and bus, commuter trains and buses) or taxi and ridesharing services. Limited visitor parking is available. Please be advised that the U.S. General Services Administration (GSA) is conducting baseline water tests at the FDA’s White Oak campus and other FDA locations. This is part of a nationwide GSA initiative assessing federal buildings for certain heavy metals and water-borne bacteria. You may see signage posted at designated water fixtures or areas. Please do not use these fixtures until signage is removed. Out of an abundance of caution, the FDA is recommending occupants refrain from consuming tap water at the White Oak campus. Where feasible, bottled water and/or water coolers are being made available for use. Sub-Topic Paragraphs Getting to FDA FDA Shuttle Bus Visitor Parking and Campus Map Campus Access and Security Public Meeting Information Meeting with FDA Staff Content current as of: 09/05/2024 Feedback Contact FDA Follow FDA on Facebook Follow FDA on X Follow FDA on Instagram Follow FDA on LinkedIn View FDA videos on YouTube Subscribe to FDA RSS feeds Contact Number 1-888-INFO-FDA (1-888-463-6332) Back to Top

Website policies

https://www.fda.gov/about-fda/resources-former-fda-employees

Last checked: 10/23/2026, 12:52:31 AM UTC

Resources for Former FDA Employees | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home About FDA Resources for Former FDA Employees About FDA In this section If you are an FDA employee who received a Reduction in Force (RIF) notice and you are at least 50 years old with 20 years of service, you may qualify for a Discontinued Service Retirement . Due to a high number of inquiries regarding benefits and retirements and to ensure immediate attention, the ERIC Help Desk (ERIC) will facilitate the intake of these inquiries. Please email ERIC@fda.hhs.gov or 301-827-3742, press option 3, then option 2 to submit your inquiry. Your assigned Benefits Specialists will be in touch as needed to ensure ample processing of your retirement package. When emailing, be sure to place the following information in the subject to ensure prompt assistance: DSR Inquiry – Your Full Name . Important Information July 17, 2025: Benefits and Pay Information July 16, 2025: Options for Returning Government Property July 16 - August 15, 2025 Additional Resources Seeking, Negotiating, and Post Employment Restrictions For ethics questions, contact the FDA Ethics Advice Hotline at FDAEthicsAdvice@fda.hhs.gov or call 240-402-1111. Content current as of: 07/29/2025 Feedback Contact FDA Follow FDA on Facebook Follow FDA on X Follow FDA on Instagram Follow FDA on LinkedIn View FDA videos on YouTube Subscribe to FDA RSS feeds Contact Number 1-888-INFO-FDA (1-888-463-6332) Back to Top

Website information

https://www.fda.gov/about-fda/about-website/accessibility-fda

Last checked: 10/23/2026, 12:52:31 AM UTC

- Skip to main content - Skip to FDA Search - Skip to in this section menu - Skip to footer links An official website of the United States government Here’s how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. - Search - Menu Search FDASubmit search Featured - Report a Product Problem - Contact FDA - FDA Guidance Documents - Recalls, Market Withdrawals and Safety Alerts - Press Announcements - Warning Letters - Advisory Committees - En Español Products - Food - Drugs - Medical Devices - Radiation-Emitting Products - Vaccines, Blood, and Biologics - Animal and Veterinary - Cosmetics - Tobacco Products Topics - About FDA - Combination Products - Regulatory Information - Safety - Emergency Preparedness - International Programs - News and Events - Training and Continuing Education - Inspections and Compliance - Science and Research Information For - Consumers - Patients - Industry - Health Professionals - Federal, State and Local Officials 1. Home 2. About FDA 3. About This Website 4. Accessibility @ FDA 1. About This Website In this section - Accessibility @ FDA - Accessibility for Windows Media Player Videos: Captions - Accessibility Guidance and Checklists - Accessible Web Conferences and Webinar Best Practices - FDA Site Accessibility Features Accessibility @ FDA - Accessibility @ FDA - Accessibility for Windows Media Player Videos: Captions - Accessibility Guidance and Checklists - Accessible Web Conferences and Webinar Best Practices - FDA Site Accessibility Features Accessibility Statement The Food and Drug Administration (FDA) is committed to providing accessible Information and Communication Technology (ICT), including third-party content published on FDA's intranet and internet websites or contained within FDA's software and web applications, to individuals with disabilities, including members of the public and federal employees, by meeting or exceeding the requirements of Section 508 of the Rehabilitation Act of 1973, as amended (29 U.S.C. § 794d). Section 508 requires agencies, during the procurement, development, maintenance, or use of ICT, to make sure that individuals with disabilities have access to and use of ICT information and data comparable to the access and use afforded to individuals without disabilities (i.e., “ICT accessibility”), unless an undue burden would be imposed on the agency. The Section 508 standards are the technical requirements and criteria that are used to measure conformance with the law and incorporates the W3C Web Content Accessibility Guidelines (WCAG) 2.0. More information on Section 508 and the technical standards can be found on Section508.gov and HHS.gov. - Section 508 Law - HHS Web Accessibility Statement - U.S. Access Board: Revised 508 Standards and 255 Guidelines Third-Party Content Policy According to the U.S. Access Board, E205.2 Public Facing section, under Section 508 of the Rehabilitation Act (as amended), Federal agencies have responsibility for all content that they develop, procure, maintain, or use. 29 U.S.C. 794d. Federal agencies are therefore responsible for third-party content added to and maintained on their sites and will need to develop policies and practices to ensure the accessibility of that third-party content. If an agency invokes an exception and uses inaccessible ICT to provide information and data to the public, the statute requires that the agency provide the same information and data to individuals with disabilities by an alternative means. For additional information, refer to E205.2 Public Facing. Report Accessibility Problem Alternate Access to Web Information At this time, all FDA information should be accessible via screen readers and other accessibility tools with the exception of some pre-2001 information, Dockets, and some technical documents. This information may not be available in accessible formats. - If you need an alternative means of access to any information on the FDA Web site please contact us. Let us know the nature of your accessibility problem, the Web address of the requested information, and your contact information. - If you need to convert PDF documents, Adobe® offers conversion tools at its Accessibility Resource Center External Link Disclaimer. If you would like to report an accessibility problem with any FDA websites, please e-mail the FDA 508 Coordinator (FDA508Coordinator@fda.hhs.gov) using the form below. To ensure we respond in a manner most helpful to you, please share the nature of your accessibility problem, the best format in which to receive the material, the web address (URL) of the material with which you are having difficulty, and your contact information. Name\ Phone Number\ Email Address\ Web Address (URL)\ Comments\ - Content current as of: 05/09/2023 Feedback form Success Thank you. Your feedback has been received. Error alert message Was this page helpful? \ Yes No Submit An official form of the United States government. Provided by Touchpoints Feedback - FDA Archive - About FDA - Accessibility - Visitor Information - Website Policies / Privacy - No FEAR Act - Vulnerability Disclosure Policy - FOIA - HHS.gov - USA.gov Contact FDA Follow FDA on Facebook Follow FDA on X Follow FDA on Instagram Follow FDA on LinkedIn View FDA videos on YouTube Subscribe to FDA RSS feeds Contact Number 1-888-INFO-FDA (1-888-463-6332) Back to Top .png) FDA.gov Site Customer Feedback Help us improve FDA.gov! We will use your responses to improve the experience for millions of people who visit FDA.gov. A red asterisk (\) indicates a required field. Success Thank you. Your feedback has been received. Error alert message 1\. Which of the following best categorizes the information you were looking for on FDA.g

Customer review source

https://www.trustpilot.com/review/fda.gov

Last checked: 10/23/2026, 12:52:23 AM UTC

Trustpilot listing for fda.gov. TrustScore: 2.1/5. Total reviews: 10. Review excerpt: A woman named Dellupac stalked me there six months after I applied in 2022, driven by her hatred of migrants, women, and everyone else. Review excerpt: To me the FDA should be to protect consumers from detrimental pharmaceutical products. Well for me the FDA has Failed!!!!! Review excerpt: Depression add on meds that "may" cause you weight gain, permanent body movements, suicidal tendencies, etc., etc.????? THIS IS THE BEST WE CAN EXPECT???? Review excerpt: They need to held accountable for approving drugs such as invega sustenna, which is said to be for schizophrenia people, not true, it's those nanometer sized little robots injected into human's blood stream Review excerpt: Easy forms to fill out, even if you don't have all the info. Review excerpt: I'd feel a whole lot safer if they were getting these contaminated drugs off the market a whole lot faster. Review excerpt: FDA is responsible for the death of my cat and so many other pets illness's and deaths!

Possible source to check

https://www.fda.gov/about-fda/fda-organization

Last checked: 10/23/2026, 12:52:23 AM UTC

We found a possible source, but could not read its page. Its contents are not included in the findings.

Possible source to check

https://www.usa.gov/agencies/food-and-drug-administration

Last checked: 10/23/2026, 12:52:23 AM UTC

We found a possible source, but could not read its page. Its contents are not included in the findings.

Possible source to check

https://www.reddit.com/r/Zepbound/comments/1futgcx/fda_says_shortage_is_over

Last checked: 10/23/2026, 12:52:49 AM UTC

We found a possible source, but could not read its page. Its contents are not included in the findings.

Possible source to check

https://www.reddit.com/r/TherapeuticKetamine/comments/1w8drk3/fda_recalls_iv_fluids_due_to_fiberglass_other

Last checked: 10/23/2026, 12:52:49 AM UTC

We found a possible source, but could not read its page. Its contents are not included in the findings.

Possible source to check

https://www.reddit.com/r/medicine/comments/brekwt/medtronic_pump_recall_the_food_and_drug

Last checked: 10/23/2026, 12:52:49 AM UTC

We found a possible source, but could not read its page. Its contents are not included in the findings.

Possible source to check

https://www.reddit.com/r/smallbusiness/comments/197oqg1/any_advice_for_a_reliable_fdaus_agent/

Last checked: 10/23/2026, 12:52:49 AM UTC

We found a possible source, but could not read its page. Its contents are not included in the findings.

Possible source to check

https://www.reddit.com/r/Dryeyes/comments/1rw73ui/new_drug_reproxalap_rejected_by_fda_disappointing

Last checked: 10/23/2026, 12:52:49 AM UTC

We found a possible source, but could not read its page. Its contents are not included in the findings.